30th Oct 2015 07:59
LONDON (Alliance News) - Hutchison China MediTech Ltd on Friday said its Hutchison China MediPharma Ltd research and development unit has completed its first in-human clinical trial on the HMPL-523 treatment.
The safety profile of the inhibitor, which targets spleen tyrosine kinase, was in line with Hutchison's expectations, with no off-target toxicities, such as hypertension or severe diarrhoea observed. The full results from the phase 1 study will be published in due course, Hutchison said.
"We have now established what we believe is a dose range for the further development of HMPL-523. This will now allow Chi-Med to move this important, potentially first-in-class compound into global Phase II proof-of-concept studies against multiple indications both in autoimmune diseases and oncology," said Chief Executive Christian Hogg.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
Hutchmed